Interferon alfa-2 - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Interferons

Antiviral drugs (excluding HIV)

Included in the formulation

Intel®-P

lyophilizate for injections

GosNII OCHB FMBA, FSUE Russia

Infagel

gel locally externally

VECTOR-MEDICA, CJSC Russia

Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

VED

ONLS

АТХ:

L.03.A.B.01 Interferon alfa

Pharmacodynamics:

The drug exhibits antiviral activity, suppressing the replication of viral RNA and DNA. Stimulates the phagocytic activity of macrophages, also promotes the increase of specific cytotoxicity of lymphocytes, has antitumor, pyrogenic and antimicrobial effect.

Pharmacokinetics:

The drug is not absorbed in the gastrointestinal tract, with subcutaneous and intramuscular injection of bioavailability of more than 80%. Does not penetrate the blood-brain barrier. Excreted by the kidneys, the half-life is 6-8 hours with intramuscular injection, 3.7-8.5 hours with intravenous infusion, 7.3 hours with subcutaneous injection, 3.8 hours with intramuscular injection.

Indications:

- aboutstriaee and chronic forms of hepatitis;

- viral keratoconjunctivitis, conjunctivitis, keratouveitis, keratitis;

- herpetic lesions of mucous membranes and skin;

- acute respiratory viral infection;

- flu;

- Kaposi's sarcoma associated with AIDS;

- kidney cancer;

- malignant skin lymphoma;

- chronic myelogenous leukemia;

- subleukemic myelosis;

- histocytosis X;

- thrombocytosis is essential;

- keratoacanthoma;

- multiple sclerosis.

The exact dose is determined by the attending physician depending on the individual parameters of the patient and his disease.

Ointment

- viral (including herpetic) lesions of the skin and mucous membranes of different locations;

- treatment of influenza and acute respiratory viral infections in children aged 1 year.

Gel

- in complex therapy acute respiratory viral infections, including flu, frequent and prolonged acute respiratory viral infections, including complicated by bacterial infection;

- prevention acute respiratory viral infections, including influenza;

- in the complex therapy of recurrent stenosing laryngotraheobronchitis;

- prevention of recurrent stenosing laryngotraheobronchitis;

- in the complex therapy of acute and exacerbations of chronic recurrent herpetic infection of the skin and mucous membranes, including urogenital form of herpetic infection;

- in the complex therapy of herpetic cervicitis.

Suppositories

In complex therapy:

- acute respiratory viral infections, including influenza, including complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults;

- infectious and inflammatory diseases of newborn children, including premature: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, tstotaligalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis);

- chronic viral hepatitis B, C, D in children and adults, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity complicated by cirrhosis of the liver;

- Infectious and inflammatory diseases of the urogenital tract (chlamydia, tstotaligalovirus infection, ureaplasmosis, trichomoniasis, gardnerellez, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults;

- primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate-to-moderate course, including urogenital form in adults.

ICD-10

I.A30-A49.A41.9 Septicemia, unspecified

I.A30-A49.A49.3 Infection caused by mycoplasma, unspecified

I.A50-A64.A59.0 Urogenital trichomoniasis

I.A70-A74.A74.9 Chlamydial infection, unspecified

I.B00-B09.B00.0 Herpetic eczema

I.B15-B19.B18 Chronic viral hepatitis

I.B25-B34.B25.9 Cytomegalovirus disease, unspecified

I.B25-B34.B34 Viral infection of unspecified site

I.B35-B49.B37.3 Candidiasis of the vulva and vagina (N77.1 *)

VI.G00-G09.G03.9 Meningitis, unspecified

X.J00-J06.J06 Acute upper respiratory tract infections of multiple and unspecified sites

X.J10-J18.J11 Influenza, virus not identified

X.J10-J18.J18 Pneumonia without clarification of the pathogen

XIV.N30-N39.N39.0 Urinary tract infection without established localization

XIV.N70-N77.N76 Other inflammatory diseases of the vagina and vulva

XV.O30-O48.O35.3 Fetal infection (presumed) as a result of a mother's viral illness, requiring the provision of medical assistance to the mother

XV.O30-O48.O35.8 Other abnormalities and fetal lesions (presumed) requiring maternal care

Contraindications:

Pregnancy, tsevere forms of allergic diseases, gand sensitivity.

Carefully:

No data.

Pregnancy and lactation:

Category FDA not determined. The drug is contraindicated in pregnancy.

Dosing and Administration:

Intramuscularly: 1 million IU twice a day, the duration of application is 5-6 days, then the dose can be reduced to 1 million IU once a day and the course is continued for 5 more days. With prolonged hepatitis, the course can be 2-12 months.

Intranasal with influenza and acute respiratory viral infections 3 drops 5-6 times a day.

Ointment, externally and topically.

When herpetic infection ointment is applied a thin layer on the lesions 3-4 times a day and gently rub. Duration of treatment is 5-7 days. It is recommended to start treatment immediately with the appearance of the first signs of skin and mucous membrane damage (itching, burning, redness). In the treatment of recurrent herpes it is desirable to begin treatment in the prodromal period or at the very beginning of the appearance of signs of relapse.

For the treatment of influenza and other acute respiratory viral infections ointment is applied a thin layer on the mucous membrane of the nasal passages 3-4 times a day the whole period of the disease.

Children from 1 year to 2 years 3 times a day, from 2 to 12 years 4 times a day, apply a thin layer, distributing evenly in both nasal passages the entire period of the disease.

Gel, externally and topically.

In complex therapy acute respiratory viral infections, including influenza, prolonged and frequent acute respiratory viral infections, including complicated by a bacterial infection: a strip of gel with a length of no more than 0.5 cm is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 3-5 times a day with a spatula or cotton swab / cotton swab. The course of treatment is 5 days, if necessary, the course can be extended.

Prevention acute respiratory viral infections, including influenza: during the period of the incidence of the incidence, a strip of gel with a length of no more than 0.5 cm is applied to the previously dried surface of the nasal mucosa and / or to the surface of the palatine tonsils 2 times a day for 2-4 weekspruce.

In the complex therapy of recurrent stenosing laryngotraheobronchitis: a strip of gel with a length of not more than 0.5 cm is applied to the surface of the tonsils using a spatula or cotton swab / cotton swab in the acute period of the disease 5 times a day, for 5-7 days, then 3 times a day during the following 3 weeks.

Prevention of recurrent stenosing laryngotraheobronchitis: a strip of gel no longer than 0.5 cm is applied to the surface of the tonsils using a spatula or cotton swab / cotton swab 2 times a day for 3-4 weeks, the courses are repeated 2 times a year.

In the complex therapy of acute and chronic recurrent herpetic infection (with the appearance of the first signs of the disease or during the precursors): a strip of gel with a length of not more than 0.5 cm is applied with a spatula or cotton swab / cotton swab on the pre-dried affected surface 3-5 times a day for 5-6 days, if necessary, the duration of the course is increased until the disappearance of clinical manifestations.

In the complex therapy of herpetic cervicitis: 1 ml of the gel is applied with a cotton swab on the pre-cleaned surface of the cervix 2 times a day for 7 days, if necessary, the duration of the course can be increased to 14 days.

Side effects:

From the gastrointestinal tract: decreased appetite, vomiting, diarrhea, nausea.

From the side of the circulatory system: cardiotoxicity, leukopenia, thrombosis, autoimmune hemolytic anemia, bleeding, autoimmune thrombocytopenia, thrombocytopenia.

From the urinary system: kidney disease, nephrotic syndrome, proteinuria.

From the respiratory system: shortness of breath, cough, discharge from the nose, nosebleeds, pneumonitis, pulmonary edema, dry mouth, pneumonitis, pharyngitis, pulmonary edema.

From the nervous system: neurotoxicity, taste changes, depression, convulsions, changes in the electroencephalogram, paresthesia, dizziness, pronounced drowsiness, coma, stroke.

From the viewpoint: hyperemia of the mucous membrane of the eye, edema of the conjunctiva of the lower arch (with topical application), blurred vision, subconjunctival hemorrhages, conjunctival infection, single follicles (with topical application), opacity, ischemic retinopathy, irreversible loss of vision in patients not suffering from diabetes.

Overdose:

Not described, treatment is symptomatic.

Interaction:

Theophylline - reduced theophylline clearance.

Myelo-depressants - dose-dependent myelotoxicity.

Acenocoumarol, warfarin - strengthening the effect of these medicines.

Paracetamol is an increase in the activity of hepatic enzymes.

Means that inhibit the nervous system - an increase in the inhibition of the nervous system.

Means that have unpredictable dose-independent myelotoxicity - increased leukopenia and / or thrombocytopenia.

Do not use concomitantly with vasoconstrictive drugs for intranasal use.

Special instructions:

On the mucous membrane of the nasal cavity, the gel is applied after cleansing the nasal passages, on the surface of the tonsils - 30 minutes after eating. When applying the gel to the palatine tonsils, do not touch the tonsils with a cotton swab, but only with gel, while the gel itself flows down the surface of the amygdala. When applying the gel to the cervix, you must first remove the mucus and gauze swab and mucus discharge from the vaults of the vagina and cervix.

When applying the gel to the affected skin and mucous membranes after 30-40 minutes a thin film is formed, on which the drug is again applied. If desired, the film can be peeled off or washed off with water before re-applying the preparation.

Impact on the ability to manage motor transport and other technical devices

Not found.

Instructions

Interferon alfa-2 (Interferonum alpha-2)